Company news
Tempest Therapeutics, Inc. news in 2025
Tempest Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
November 26, 2025
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
November 25, 2025
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
November 19, 2025
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
November 5, 2025
Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer
August 13, 2025
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
August 11, 2025
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
June 30, 2025
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
June 11, 2025
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
June 5, 2025
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
April 28, 2025
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
April 21, 2025
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
April 9, 2025
Tempest Reports Year End 2024 Financial Results and Provides Business Update
March 27, 2025
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
March 25, 2025
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
March 13, 2025
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
February 9, 2025
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 6, 2025
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
January 5, 2025